#orally

BBO-11818: An Orally Bioavailable Pan-KRAS Inhibitor for KRAS-related Cancer Research

KRAS is a major oncogenic driver in multiple cancers, with clinically relevant mutations including KRASG12D, KRASG12V, and KRASG12C…